Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes-Reference-Cited by-同舟云学术

Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes

Published:2021-07 Issue:10 Volume:22 Page:603-618
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Sahana S¹^ORCID,Sivadas Ambily²,Mangla Mohit¹³,Jain Abhinav¹³,Bhoyar Rahul C¹,Pandhare Kavita¹,Mishra Anushree¹,Sharma Disha¹,Imran Mohamed¹³,Senthivel Vigneshwar¹³,Divakar Mohit Kumar¹³,Rophina Mercy¹³,Jolly Bani¹³,Batra Arushi¹³,Sharma Sumit¹,Siwach Sanjay¹,Jadhao Arun G⁴,Palande Nikhil V⁵,Jha Ganga Nath⁶,Ashrafi Nishat⁶,Mishra Prashant Kumar⁷,Vidhya AK⁸,Jain Suman⁹,Dash Debasis¹³,Kumar Nachimuthu Senthil¹⁰,Vanlallawma Andrew¹⁰,Sarma Ranjan Jyoti¹⁰,Chhakchhuak Lalchhandama¹¹,Kalyanaraman Shantaraman¹²,Mahadevan Radha¹²,Kandasamy Sunitha¹²,Devi Pabitha¹²,Rajagopal Raskin Erusan¹²,Ramya J Ezhil¹²,Devi P Nirmala¹²,Bajaj Anjali¹³,Gupta Vishu¹³,Mathew Samatha¹³,Goswami Sangam¹³,Prakash Savinitha¹,Joshi Kandarp¹,Kumla Meya¹,Sreedevi S¹³,Gajjar Devarshi¹⁴,Soraisham Ronibala¹⁵,Yadav Rohit¹³,Devi Yumnam Silla¹⁶,Gupta Aayush¹⁷,Mukerji Mitali¹³,Ramalingam Sivaprakash¹³,Binukumar BK¹³,Sivasubbu Sridhar¹³,Scaria Vinod¹³

Affiliation:

1. CSIR Institute of Genomics & Integrative Biology, Mathura Road, New Delhi, 110025, India

2. Division of Nutrition, St. John’s Research Institute, St. John’s National Academy of Health Sciences, Bangalore, India

3. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, 201002, India

4. Department of Zoology, RTM Nagpur University, Nagpur, Maharashtra, 440033, India

5. Department of Zoology, Shri Mathuradas Mohota College of Science, Nagpur, Maharashtra, 440009, India

6. Department of Anthropology, Vinoba Bhave University, Hazaribag, Jharkhand, 825301, India

7. Department of Biotechnology, Vinoba Bhave University, Hazaribag, Jharkhand, 825301, India

8. Department of Biochemistry, Dr. Kongu Science & Art College, Erode, Tamil Nadu, 638107, India

9. Thalassemia & Sickle cell Society, Hyderabad, Telangana, 500052, India

10. Department of Biotechnology, Mizoram University, Aizawl, Mizoram, 796004, India

11. Department of Pathology, Civil Hospital Aizawl, Mizoram, 796001, India

12. TVMC, Tirunelveli Medical College, Tirunelveli, Tamil Nadu, 627011, India

13. Department of Microbiology, St. Pious X Degree & PG College for Women, Hyderabad, Telangana, 500076, India

14. Department of Microbiology, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, 390002, India

15. Department of Dermatology, Venereology & Leprology, Regional Institute of Medical Sciences, Imphal, Manipur, 795004, India

16. CSIR- North East Institute of Science & Technology, Jorhat, Assam, 785006, India

17. Department of Dermatology, Dr. D.Y. Patil Medical College, Pune, Maharashtra, 411018, India

Abstract

Aim: Numerous drugs are being widely prescribed for COVID-19 treatment without any direct evidence for the drug safety/efficacy in patients across diverse ethnic populations. Materials & methods: We analyzed whole genomes of 1029 Indian individuals (IndiGen) to understand the extent of drug–gene (pharmacogenetic), drug–drug and drug–drug–gene interactions associated with COVID-19 therapy in the Indian population. Results: We identified 30 clinically significant pharmacogenetic variants and 73 predicted deleterious pharmacogenetic variants. COVID-19-associated pharmacogenes were substantially overlapped with those of metabolic disorder therapeutics. CYP3A4, ABCB1 and ALB are the most shared pharmacogenes. Fifteen COVID-19 therapeutics were predicted as likely drug–drug interaction candidates when used with four CYP inhibitor drugs. Conclusion: Our findings provide actionable insights for future validation studies and improved clinical decisions for COVID-19 therapy in Indians.

Funder

The council of scientific and industrial research, India

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2021-0028

Reference48 articles.

1. Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics

2. Pharmacogenomics of COVID-19 therapies

3. COVID‐19: A Defining Moment for Clinical Pharmacology?

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The therapeutic landscape for COVID-19 and post-COVID-19 medications from genetic profiling of the Vietnamese population and a predictive model of drug-drug interaction for comorbid COVID-19 patients;Heliyon;2024-03

2. Landscape of pharmacogenetic variants associated with non-insulin antidiabetic drugs in the Indian population;BMJ Open Diabetes Research & Care;2024-03

3. Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions;European Journal of Drug Metabolism and Pharmacokinetics;2023-04-24

4. Public Health Issues in Pharmacogenomics;Pharmacogenomics in Clinical Practice;2023

5. Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach;The Pharmacogenomics Journal;2022-09-28